Latest news with #HumbiAI
Business Wire
05-05-2025
- Health
- Business Wire
Humbi AI by Innovaccer Research in JAMA Shows Telepsychiatry Cuts Emergency Department Admissions by 17.9% at Similar Medicaid Costs
SAN FRANCISCO--(BUSINESS WIRE)--Humbi AI by Innovaccer, the industry's leading actuarial intelligence platform, today announced its research publication in JAMA Network focusing on "Medicaid Costs and Patient Outcomes Associated with Outpatient Telepsychiatry Clinics." This landmark study, co-researched with Frontier Psychiatry, a telepsychiatry clinic in Billings, Montana, represents Humbi AI's first research based on clinical data, showcasing its expertise in healthcare data access and analytics. The cross-sectional study leveraged Humbi AI's national Medicaid analytics platform to analyze 5,372 Montana Medicaid patients, comparing 2,686 patients who received services from Frontier Psychiatry, with an equal number of propensity-matched controls who did not use Frontier's services during the study period. The comprehensive analysis revealed significant improvements in key healthcare metrics. Key findings include: Patients using telepsychiatry services had a 38.0% lower annualized hospitalization rate compared to controls (274.3 vs. 442.6 hospitalizations per 1,000 patients) Telepsychiatry patients had 17.9% lower rate of admissions from emergency departments (47.7% vs. 58.1% of hospitalizations) Overall monthly costs to Medicaid were statistically similar between the groups ($685.50 for Frontier patients vs. $734.00 for non-Frontier patients per member per month) across all cost categories analyzed While professional service costs were higher for telepsychiatry patients, inpatient hospitalization costs were significantly lower These findings provide strong evidence that additional investment in outpatient telepsychiatry services is warranted across healthcare systems. "The best decisions in healthcare are backed by solid evidence," said Abhinav Shashank, Co-founder and CEO of Innovaccer. "And the evidence here is compelling, telepsychiatry keeps more people out of hospitals without adding costs. Since bringing Humbi AI into our family, we've been focused on delivering exactly these kinds of practical insights that help providers succeed in value-based care." Humbi AI's platform provides healthcare organizations with actuarially grounded insights into cost, utilization, and risk trends across specialties and regions. This intelligence enables providers to benchmark performance and negotiate smarter contracts, allows payers to design more sustainable reimbursement models, and helps life sciences companies align market strategies with areas of high cost or opportunity. To learn more about the research and outcomes of Humbi's actuarial intelligence, schedule a demo today. About Innovaccer Innovaccer activates the flow of healthcare data, empowering providers, payers, and government organizations to deliver intelligent and connected experiences that advance health outcomes. The Healthcare Intelligence Cloud equips every stakeholder in the patient journey to turn fragmented data into proactive, coordinated actions that elevate the quality of care and drive operational performance. Leading healthcare organizations like CommonSpirit Health, Atlantic Health, and Banner Health trust Innovaccer to integrate a system of intelligence into their existing infrastructure, extending the human touch in healthcare. For more information, visit About Humbi AI Humbi AI is an actuarial intelligence company enabling providers, payers, and life sciences organizations to manage risk, improve performance, and succeed in value-based care. With deep actuarial expertise, robust benchmarking data, and flexible financial modeling software, Humbi AI provides powerful analytics and consultative services that transform complex challenges into actionable insights. By simplifying risk management and enhancing decision-making, Humbi AI helps organizations drive better outcomes and sustainable growth. For more information, visit
National Post
30-04-2025
- Business
- National Post
Humbi AI by Innovaccer and Landmark Science to Present Real-World Evidence on GLP-1 Use for Cardiometabolic and Cardiovascular Risk Reduction in Medicare Populations at ISPOR 2025
Article content Article content Article content MONTREAL — Innovaccer, the leading healthcare AI company, today announced that its recently acquired actuarial science company – Humbi AI, in collaboration with Landmark Science, Inc., will present a joint research at the upcoming International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025 annual conference, scheduled to take place between May 13–16 in Montreal, QC, Canada. Article content The research offers new insights into the characteristics of Medicare patients initiating GLP-1 receptor agonists (RAs) and Wegovy (semaglutide) for cardiometabolic and cardiovascular risk reduction. Article content The research, leveraging Humbi AI's high-quality real-world Medicare dataset, provides a timely look into patient populations initiating these therapies—an area of growing importance as GLP-1 RAs expand beyond diabetes management. Article content 'The rapid adoption of GLP-1s like semaglutide in cardiometabolic care highlights a critical need for real-world data to inform access, outcomes, and equity,' said Puneet Budhiraja – Vice President, Analytics at Humbi AI by Innovaccer. 'At ISPOR, we're excited to share data that helps stakeholders better understand who is initiating these therapies – and who might be left behind.' Article content 'The importance of real-world evidence in understanding semaglutide's impact on cardiovascular disease among Medicare patients cannot be overstated, particularly given the risk of heart attack and stroke among this older population,' said Shivani Aggarwal – CEO of Landmark Science. Article content The two joint poster presentations by HumbiAI and Landmark Science, Inc. include: Article content Poster #EPH74 (Poster Session 2, 14th May, 4:00PM – 7:00PM): Characteristics of Patients Initiating Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (RAs) for Cardiometabolic Risk Reduction in a Medicare Population This study analyzes patient demographics, comorbidities, and outcomes among Medicare beneficiaries initiating any GLP-1 RAs, shedding light on the populations adopting these treatments. View Poster Abstract Article content Humbi AI by Innovaccer is an actuarial intelligence company powered by Medicare, Medicaid, and Commercial datasets enabling providers, payers, and life sciences organizations to manage risk, improve performance, and succeed in value-based care. With deep actuarial expertise, robust benchmarking data, and flexible financial modeling software, Humbi AI provides powerful analytics and consultative services that transform complex challenges into actionable insights. By simplifying risk management and enhancing decision-making, Humbi AI by Innovaccer helps organizations drive better outcomes and sustainable growth. For more information, visit Article content Article content Article content Article content Article content Contacts Article content Article content Article content
